Chitose Supercell will revolutionise the world’s antibody drug manufacturing process

cell engineering, antibody drug manufacturing, biologics manufacturing, master cell bank development, cell line development, CHO cell, mammalian cell line

“We want to implement this platform into the biologics production so that biopharmaceutical can be prescribed more easily ”

In the world, the demand for regenerative medicine and medicine for unmet medical needs (illnesses for which no cure has been found) is increasing every day. CHITOSE is aiming to speed up and reduce costs of the world’s antibiotics manufacturing process by using a super cell to contribute to global healthcare.
As a leader in the host cell market, we are developing new CHO cells that boast the world's highest production efficiency of antibody drugs, through the collaboration with AMED, as well as domestic and overseas biopharmaceutical companies.

Background issues

In order to reduce the ever soaring price of antibody drugs, high efficiency and low manufacturing process costs are required.

Our technologies

Technology to create diversity in a uniform cell pool and develop cells with several outstanding characteristics
Technology to screen for cells with desired characteristics from various cell pools
Technology to establish immortalized cell lines from primary tissue culture
Technology to develop test methods to comply with regulations for drug application

Current status

We collaborate with domestic and international biopharmaceutical companies and universities, providing contract development services for therapeutic recombinant protein–producing cell lines using CHO-MK cells. To date, we have completed more than 50 development projects and continue to expand our market share.

Locations

Japan, United States, Europe, Asia

Partner

Bio-related companies: pharmaceutical companies, reagent and diagnostic companies, culture media manufacturers, CROs, CDMOs, and others.